Publication Date
1-28-2020
Journal
Cancer Letters
DOI
10.1016/j.canlet.2019.11.020
PMID
31734355
PMCID
PMC9017243
PubMedCentral® Posted Date
4-19-2022
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Adenocarcinoma, Biomarkers, Tumor, Carcinogenesis, Carcinoma, Pancreatic Ductal, Disease Progression, Humans, Mutation, Neoplasm Proteins, Protein Processing, Post-Translational, Proteome, Proteomics, Pancreatic cancer, Proteomics, Mass spectrometry, Post-translational modification, Glycosylation
Abstract
Proteins are the essential functional biomolecules profoundly implicated in all aspects of pancreatic tumorigenesis and its progression. While common genomic factors, such as KRAS, TP53, SMAD4, and CDKN2A have been well recognized in association of pancreatic ductal adenocarcinoma (PDAC), our understanding of functional changes at the proteome level merits further investigation. Malignance associated proteome alterations can be attributed to the convoluted outcomes from genetic, epigenetic and environmental factors in initiating and progressing PDAC, and may reflect on changes in protein expressional level, structure, localization, as well as post-translational modifications (PTMs) status. The study of localized or systemic proteome alterations in PDAC, as well as its precursor lesions, such as pancreatic intraepithelial neoplasia (PanIN) and mucinous pancreatic cystic neoplasm, would provide unique perspectives in elucidating functional molecular events underlying PDAC. While efforts have been made, challenges still exist to comprehensively integrate much of the proteomic discovery to the perspectives gained from genomic studies in the context of biomarker discovery. Novel approaches and data from well-defined longitudinal clinical studies and experimental models are needed to facilitate the study of PDAC and precursor lesions for early detection and intervention.
Included in
Digestive System Diseases Commons, Gastroenterology Commons, Medical Sciences Commons, Oncology Commons